Literature DB >> 35027692

FDA approves first-in-class TSLP-targeted antibody for severe asthma.

Asher Mullard.   

Abstract

Entities:  

Year:  2022        PMID： 35027692     DOI： 10.1038/d41573-022-00013-5

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  1 in total

1.  Autocrine motility factor receptor as a therapeutic target for asthma: comments on 'AMFR drives allergic asthma development by promoting alveolar macrophage-derived GM-CSF production'.

Authors:  Huihui Zhang; Feng Qian; Lei Sun
Journal:  J Mol Cell Biol       Date:  2022-08-26       Impact factor: 8.185
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.